Biosidus is a Biopharmaceutical company, Generics/Biosimilars Manufacturer company operating in the pharmaceutical industry.
Biosidus is engaged in the development, manufacturing and commercialization of high-quality recombinant proteins. Since the launch of Erythropoetin in 1990, Biosidus has successively marketed the following biosimilars: Interferon Alfa 2a, Interferon Alfa 2b, Filgrastim, Somatropin, Lenograstim, Azacitidine, Bortezomib, Interferon beta 1a (SC and IM) and Teriparatide. Today, these products are being commercialized in more than 50 markets.
Company type
Biopharmaceutical company, Generics/Biosimilars Manufacturer
Products and services
Pharmaceutical Products / ATC coding, Biopharmaceuticals
Markets
Africa, Middle East Region (e.g. UAE), Central America (e.g. Mexico), East Asia (e.g. China, Japan, Korea), Europe – EU countries, Europe – non EU (e.g. UK, Russia, ex-CIS countries), South America (e.g. Brazil, Colombia), South Asia (e.g. India, Pakistan, Sri Lanka), South East Asia (e.g. Thailand, Philippines, Singapore)
Useful Links
Connect with Biosidus on LinkedIn
Address
Biosidus, Constitucion 4234, Buenos Aires, C.A.B.A, Argentina, C1254 ABX
